Business
Inspira Technologies Files a PCT Patent Application for its Flagship ART Device and Proprietary Method of Use to Minimize the Need for Mechanical Ventilation
The ART device is an early-stage extracorporeal respiratory support system designed to treat patients while awake and breathing spontaneously RA'ANANA,
About this update from Qtrex Quantum Ltd.
[{"type":"text","content":"The ART device is an early-stage extracorporeal respiratory support system designed to treat patients while awake and breathing spontaneously\n RA'ANANA, Israel, Dec. 8, 2021 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the \"Company\" or \"Inspira Technologies\"), a groundbreaking respiratory support technology company, announced today it has filed a Patent Cooperation Treaty (PCT) patent application for its novel ART device and its proprietary methods of use to minimize the need for invasive mechanical ventilation which requires intubation and induced coma.\nInspira Technologies designed the ART, a novel low-flow early extracorporeal blood oxygenation system intended to offer acute respiratory patients, who continue to deteriorate following non-invasive ventilation treatment, a new alternative to invasive mechanical ventilation. Today, despite that, at the non-invasive ventilation treatment stage, these patients are still breathing spontaneously, the only alternative treatment available to them after non-invasive ventilation has failed is invasive mechanical ventilation. \nThe ART is designed to enrich approximately 1-1.5 liters of blood in a minute to rebalance oxygen saturation levels in minutes.\nThe ART device utilizes a hemo-protective flow approach intended to increase blood oxygenation levels and remove CO2 to potentially prevent invasive mechanical ventilation and minimize the risks and complications associated with this type of treatment. \nThe ART device, a novel extracorporeal oxygenation system, is being developed for treatment of patients in order to maintain spontaneous breathing. This initiates a circulation rate of 30 ml/Kg per minute that is significantly lower than the circulation rate used in extracorporeal membrane oxygenation (ECMO) that ranges between 60-80 ml/kg/min for veno-venous ECMO and 50-60 ml/kg/min for veno-arterial ECMO¹.\nART is being mechanically engineered and designed to optimize the safety profile of low flow extracorporeal treatment due to the reduction of shear forces on the blood, therefore contributing to reducing hemolysis and blood clotting. These methods of use and mechanical design are intended to provide a safe profile of treatment potentially resulting in the following: (1) prevention or minimization of mechanical ventilation and all its associated d...